Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science. 2019;366:818–22.
Raffeiner M, Zhu S, González-Fuente M, Üstün S. Interplay between autophagy and proteasome during protein turnover. Trends Plant Sci. 2023;28:698–714.
Zhao L, Zhao J, Zhong K, Tong A, Jia D. Targeted protein degradation: mechanisms, strategies and application. Sig Transduct Target Ther. 2022;7:1–13.
Fletcher, Clift A, Vries D, de E, Martinez Cuesta S, Malcolm T, et al. A TRIM21-based bioPROTAC highlights the therapeutic benefit of HuR degradation. Nat Commun. 2023;14:7093.
Rothe C, Skerra A. Anticalin® proteins as therapeutic agents in human diseases. BioDrugs. 2018;32:233–43.
Guillard S, Kolasinska-Zwierz P, Debreczeni J, Breed J, Zhang J, Bery N, et al. Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange. Nat Commun. 2017;8:16111.
Münick P, Zielinski J, Strubel A, Gutfreund N, Dreier B, Schaefer JV, et al. DARPins as a novel tool to detect and degrade p73. Cell Death Dis. 2024;15:909.
Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA. 2001;98:8554–9.
Stebbins CE, Kaelin WG, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science. 1999;284:455–61.
Ou L, Setegne MT, Elliot J, Shen F, Dassama LMK. Protein-based degraders: from chemical biology tools to neo-therapeutics. Chem Rev. 2025;125:2120–83.
Swenson CS, Mandava G, Thomas DM, Moellering RE. Tackling undruggable targets with designer peptidomimetics and synthetic biologics. Chem Rev. 2024;124:13020–93.
Xue B, Li R, Cheng Z, Zhou X. High-affinity peptides for target protein screened in ultralarge virtual libraries. ACS Cent Sci. 2024;10:2111–8.
Chisholm CG, Bartlett R, Brown ML, Proctor EJ, Farrawell NE, Gorman J, et al. Development of a targeted BioPROTAC degrader selective for misfolded SOD1. Nat Commun. 2025;16:9713.
Zhou R, Wang H, Zhang GM, Liu Y, Liu XL, Li Z, et al. Targeted degradation of endogenous YAP by nanobody bioPROTAC inhibits tumor progression. Nat Commun. 2025;16:9374.
Wang H, Zheng Y, Wang T, Zhang X, Wang P, Wei C, et al. Structure-based engineering of the midnolin-proteasome pathway for targeted protein degradation. Protein Cell. 2026;17:83–8.
Gu X, Nardone C, Kamitaki N, Mao A, Elledge SJ, Greenberg ME. The midnolin-proteasome pathway catches proteins for ubiquitination-independent degradation. Science. 2023;381:eadh5021.
Xu Y, Zhao W, Fu J, Liu Z, Nie HJ, Zhang J, et al. Multiplexed photo-cross-linking reveals comprehensive midnolin interactome: insights into ubiquitin-independent degradation and functional diversity. J Am Chem Soc. 2026;148:11962–73.
Nardone C, Gao J, Seo HS, Mintseris J, Ort L, Yip MCJ, et al. Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma. Mol Cell. 2025;85:2597–2609.e11.
Lim S, Khoo R, Peh KM, Teo J, Chang SC, Ng S, et al. bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA). Proc Natl Acad Sci USA. 2020;117:5791–800.
Winkelvoß D, Vukovic D, Hänny AC, Riermeier L, Udovcic A, Kolibius J, et al. Molecular features defining the efficiency of bioPROTACs. Commun Biol. 2025;8:946.